Jason Aryeh Biography and Net Worth

Director of Orchestra BioMed

Mr. Aryeh is the founder and managing general partner of JALAA Equities, LP, a private hedge fund focused on the biotechnology and specialty pharmaceutical sector and has served in such capacity since 1997. He has served as a member of the board of directors of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND), a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. He has served as Ligand’s Chairman of its Nominating and Governance Committee since September 2006. He serves as the Chairman of the Board of Directors of Novelion Therapeutics and is also on the board of directors of the Cystic Fibrosis Foundation's Therapeutics Board.

What is Jason Aryeh's net worth?: The estimated net worth of Jason Aryeh is at least $412.37 thousand as of June 11th, 2026. Aryeh owns 102,580 shares of Orchestra BioMed stock worth more than $412,372 as of June 23rd. This net worth estimate does not reflect any other assets that Aryeh may own. Learn More about Jason Aryeh's net worth.
How do I contact Jason Aryeh?: The corporate mailing address for Aryeh and other Orchestra BioMed executives is 40 10TH AVENUE FLOOR 7, NEW YORK NY, 10014. Orchestra BioMed can also be reached via phone at 646-597-6980 and via email at [email protected]. Learn More on Jason Aryeh's contact information.
Has Jason Aryeh been buying or selling shares of Orchestra BioMed?: Over the course of the past ninety days, Jason Aryeh has bought $37,480.65 in shares of Orchestra BioMed stock. Most recently, on Monday, May 18th, Jason Aryeh bought 665 shares of Orchestra BioMed stock. The stock was acquired at an average cost of $3.75 per share, with a total value of $2,493.75. Following the completion of the transaction, the director now directly owns 118,118 shares of the company's stock, valued at $442,942.50. Learn More on Jason Aryeh's trading history.
Who are Orchestra BioMed's active insiders?: Orchestra BioMed's insider roster includes Jason Aryeh (Director), Eric Fain (Director), David Hochman (Chairman, Chief Executive Officerand Founder), Darren Sherman (President, Chief Operations Officer,Director and Founder), and Andrew Taylor (Chief Financial Officer). Learn More on Orchestra BioMed's active insiders.
Are insiders buying or selling shares of Orchestra BioMed?: In the last year, Orchestra BioMed insiders bought shares 13 times. They purchased a total of 92,396 shares worth more than $321,714.25. In the last year, insiders at the sold shares 2 times. They sold a total of 17,683 shares worth more than $66,233.15. The most recent insider tranaction occured on June, 1st when insider David P Hochman bought 5,000 shares worth more than $19,150.00. Insiders at Orchestra BioMed own 7.5% of the company. Learn More about insider trades at Orchestra BioMed.
Information on this page was last updated on 6/1/2026.

Jason Aryeh Insider Trading History at Orchestra BioMed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/18/2026	Buy	665	$3.75	$2,493.75	118,118
5/15/2026	Buy	8,971	$3.90	$34,986.90	117,453
9/19/2025	Buy	1,000	$2.45	$2,450.00	108,482

Jason Aryeh Buying and Selling Activity at Orchestra BioMed

Orchestra BioMed Company Overview

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Today's Range

Now: $4.04

$3.94

$4.12

50 Day Range

MA: $4.06

$3.72

$4.58

2 Week Range

Now: $4.04

$2.20

$5.42

Volume

97,588 shs

Average Volume

218,252 shs

Market Capitalization

$241.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51